Seasoned chairpersons and board members back life sciences startups

Anaveon, a clinical-stage company specializing in developing treatments for diseases with immune system dysfunction, focusing on biologics that modulate cytokine functions to provide therapeutic benefit has appointed former Chair and CEO of Bayer Pharmaceuticals, as Chair of its Board of Directors. Weinand brings extensive experience in the pharmaceutical and biotechnology sectors, having held leadership positions at notable companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi. His expertise spans various areas including product development and commercialization, which will be valuable as Anaveon advances its innovative therapies targeting cancer and autoimmune diseases.

LimmaTech Biologics welcomes new Chairperson
LimmaTech Biologics AG, a Swiss biotech company specializing in vaccine development, has appointed Staph Leavenworth Bakali as the new Chairman of its Board of Directors. Bakali brings extensive experience in the pharmaceutical and vaccine industries, having held leadership positions at major organizations such as Gavi, the Vaccine Alliance, and PATH. His expertise in global health and vaccine development aligns well with LimmaTech's focus on creating innovative vaccines for infectious diseases. The company's CEO, Christoph Rutishauser, expressed enthusiasm about Bakali's appointment, highlighting his strategic vision and industry knowledge as valuable assets for LimmaTech's growth. This appointment is expected to strengthen the company's position in the biotech sector and support its mission to develop novel vaccines addressing unmet medical needs.

Odne appoints independent board member to fuel US expansion
Odne has appointed Steve Fanning as an Independent Board Member to support its recent U.S. launch activities. Fanning has over 25 years of commercial and general management experience in healthcare, delivering consistent results driving growth with mature businesses and building growth playbooks for newer businesses.

Founded in 2018, Odne developed its flagship product, Odne™Fill, the first FDA-cleared light-curing, injectable endodontic obturation material. Odne has recently launched a Priority Access Program (PAP) for its innovative Root Preservation Therapy (RPT) at the AAE annual meeting in Los Angeles. The PAP will form the core of Odne's scientific & clinical community, transforming endodontics. One initiative of the PAP is to perform a clinical case registry, collecting further knowledge on the clinical use of Odne's devices for root canal treatment. Participating Endodontists get the chance to be amongst the first users of Odne's devices and provide valuable use-related and scientific feedback.

(RAN)